Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis
Company To Initially Target 70 Cancer Centers
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
You may also be interested in...
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
The FDA has granted full approval to the drug based on Phase I efficacy data and safety studies, reflecting lack of existing treatment options